TABLE 2.
Sorafenib pharmacokinetic parameters in male and female rats after oral administration of SOR (50 mg/kg) alone and concomitant treatment with or without of BG (160 mg/kg, i.g.) for consecutive 7 days (n = 6, each).
| PK parameter | Male | Female | ||
|---|---|---|---|---|
| Control | BG + SOR | Control | BG + SOR | |
| Cmax (μg/ml) | 0.49 ± 0.06 | 0.99 ± 0.25** | 0.77 ± 0.11## | 1.21 ± 0.08** |
| t max (h) | 4.33 ± 1.51 | 4.33 ± 1.97 | 5.00 ± 1.67 | 5.21 ± 1.09 |
| t 1/2 (h) | 9.21 ± 2.38 | 13.29 ± 5.48 | 11.84 ± 2.28 | 12.76 ± 3.16 |
| AUC0∼t (h·μg/ml) | 7.97 ± 2.62 | 13.17 ± 2.00** | 14.77 ± 1.39## | 18.43 ± 1.96** |
| AUC0∼∞ (h·μg/ml) | 8.08 ± 2.67 | 13.44 ± 2.16** | 15.15 ± 1.57## | 18.83 ± 2.10** |
| MRT0∼t (h) | 13.67 ± 3.08 | 14.07 ± 2.60 | 16.67 ± 1.50 | 15.27 ± 0.94 |
| MRT0∼∞ (h) | 14.47 ± 3.38 | 15.54 ± 3.06 | 18.46 ± 2.19 | 16.85 ± 1.18 |
| CL/F (L/h) | 6.95 ± 2.82 | 3.81 ± 0.63* | 3.33 ± 0.34## | 2.68 ± 0.30** |
| Vz/F (L) | 88.27 ± 34.75 | 69.92 ± 22.71 | 56.73 ± 11.15 | 49.29 ± 13.71 |
Values are means ± SD.
*p < 0.05, **p < 0.01 compared with the control.
## p < 0.01 compared with the male group.